Watson Pharmaceuticals, Inc. is engaging FDA “at every level” to push for the approval of progesterone gel 8% - a product widely referred to as Prochieve – CEO Paul Bisaro said during a Jan. 24 investor meeting.
That includes reaching up to the highest tier of the agency, a phone call with Commissioner Margaret Hamburg, to discuss what Watson feels was an unfair FDA advisory committee review...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?